Investment Exodus Fear for Besieged Drugs Giants; after Britain's Two Biggest Pharmaceutical Groups Are Challenged in US Courts over Patents. .

By Watkins, Simon | The Mail on Sunday (London, England), June 2, 2002 | Go to article overview

Investment Exodus Fear for Besieged Drugs Giants; after Britain's Two Biggest Pharmaceutical Groups Are Challenged in US Courts over Patents. .


Watkins, Simon, The Mail on Sunday (London, England)


Byline: SIMON WATKINS

THE drugs industry, buoyed for 20 years by blockbusters such as Viagra and Prozac, is under siege.

Drugs companies are facing an unprecedented threat from cheaper rivals flooding the market. And the severity of the assault on the multinational giants has been thrown into sharp relief within the past fortnight by high-profile cases in the American courts against Britain's two biggest drugs groups.

GlaxoSmithKline saw the patent on its key antibiotic, Augmentin, overruled.

In a separate case, Astra-Zeneca is awaiting judgment on the patent for its antacid drugs Losec and Prilosec.

Both companies can appeal against adverse rulings, but investors have already taken flight, sending shares diving amid severe profits downgrades by City analysts.

Patents on leading drugs developed in the Eighties and early Nineties are running out and cheaper copycat, or generic, products are threatening to muscle in on the market. At the same time, the number of new drugs being developed by the pharmaceutical giants is shrinking.

Meanwhile, governments in developed countries are keen to improve efficiency in their health services, which means pressure on suppliers to reduce costs.

Epidemics such as HIV/AIDS in Africa have led many to question whether patents on lifesaving but expensive drugs or vaccines should simply be ignored in the interests of public health.

Stockbroking agency Charles Stanley claimed: 'The Augmentin case showed that US courts can overturn patent protection that investors have come to rely on to maintain topline growth. And the huge research and development commitment required to keep the drug pipeline full is growing, not receding.' The threat to each drug company has led to rumours that the giants will merge to help pool their risks.

Only days ago, Glaxo was tipped to be in talks with American rival Bristol-Myers, though no deal is believed to be imminent. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Investment Exodus Fear for Besieged Drugs Giants; after Britain's Two Biggest Pharmaceutical Groups Are Challenged in US Courts over Patents. .
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.